A malignant epithelial neoplasm of the kidney characterized by the presence of lipid-containing clear cells within a vascular network. The tumor may metastasize to unusual sites and late metastasis is...
Comprehensive, easy-to-understand information about this condition
How we create this content →The documentation for clear cell renal carcinoma is limited due to its relatively rare occurrence and the complexity of its clinical features. Because this condition affects fewer than 200,000 people in the United States, there have been fewer systematic studies conducted. Additionally, the lack of identified genetic factors complicates the understanding of its etiology and clinical manifestations.
To navigate your care effectively, consider seeking a specialist in oncology with experience in renal cancers, particularly clear cell renal carcinoma. Engaging with a clinical trial may also provide access to cutting-edge treatments; check the active trials listed on ClinicalTrials.gov. Additionally, while no specific patient organizations are identified, resources like GARD (rarediseases.info.nih.gov) can provide valuable information and support. Participating in a natural history study could also contribute to the understanding of this condition.
Currently, there are 177 active clinical trials exploring various aspects of clear cell renal carcinoma. One notable orphan drug designated for this condition is Interleukin-2, while Aldesleukin is FDA-approved for treatment. For more information on ongoing trials, you can visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=clear%20cell%20renal%20carcinoma. This research landscape offers hope for new therapeutic options and better understanding of the disease.
Actionable guidance for navigating care for clear cell renal carcinoma
To navigate your care effectively, consider seeking a specialist in oncology with experience in renal cancers, particularly clear cell renal carcinoma. Engaging with a clinical trial may also provide access to cutting-edge treatments; check the active trials listed on ClinicalTrials.gov. Additionally, while no specific patient organizations are identified, resources like GARD (rarediseases.info.nih.gov) can provide valuable information and support. Participating in a natural history study could also contribute to the understanding of this condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation for clear cell renal carcinoma is limited due to its relatively rare occurrence and the complexity of its clinical features. Because this condition affects fewer than 200,000 people in the United States, there have been fewer systematic studies conducted. Additionally, the lack of identified genetic factors complicates the understanding of its etiology and clinical manifestations.
To navigate your care effectively, consider seeking a specialist in oncology with experience in renal cancers, particularly clear cell renal carcinoma. Engaging with a clinical trial may also provide access to cutting-edge treatments; check the active trials listed on ClinicalTrials.gov. Additionally, while no specific patient organizations are identified, resources like GARD (rarediseases.info.nih.gov) can provide valuable information and support. Participating in a natural history study could also contribute to the understanding of this condition.
Currently, there are 177 active clinical trials exploring various aspects of clear cell renal carcinoma. One notable orphan drug designated for this condition is Interleukin-2, while Aldesleukin is FDA-approved for treatment. For more information on ongoing trials, you can visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=clear%20cell%20renal%20carcinoma. This research landscape offers hope for new therapeutic options and better understanding of the disease.
Actionable guidance for navigating care for clear cell renal carcinoma
To navigate your care effectively, consider seeking a specialist in oncology with experience in renal cancers, particularly clear cell renal carcinoma. Engaging with a clinical trial may also provide access to cutting-edge treatments; check the active trials listed on ClinicalTrials.gov. Additionally, while no specific patient organizations are identified, resources like GARD (rarediseases.info.nih.gov) can provide valuable information and support. Participating in a natural history study could also contribute to the understanding of this condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation for clear cell renal carcinoma is limited due to its relatively rare occurrence and the complexity of its clinical features. Because this condition affects fewer than 200,000 people in the United States, there have been fewer systematic studies conducted. Additionally, the lack of identified genetic factors complicates the understanding of its etiology and clinical manifestations.
To navigate your care effectively, consider seeking a specialist in oncology with experience in renal cancers, particularly clear cell renal carcinoma. Engaging with a clinical trial may also provide access to cutting-edge treatments; check the active trials listed on ClinicalTrials.gov. Additionally, while no specific patient organizations are identified, resources like GARD (rarediseases.info.nih.gov) can provide valuable information and support. Participating in a natural history study could also contribute to the understanding of this condition.
Currently, there are 177 active clinical trials exploring various aspects of clear cell renal carcinoma. One notable orphan drug designated for this condition is Interleukin-2, while Aldesleukin is FDA-approved for treatment. For more information on ongoing trials, you can visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=clear%20cell%20renal%20carcinoma. This research landscape offers hope for new therapeutic options and better understanding of the disease.
Actionable guidance for navigating care for clear cell renal carcinoma
To navigate your care effectively, consider seeking a specialist in oncology with experience in renal cancers, particularly clear cell renal carcinoma. Engaging with a clinical trial may also provide access to cutting-edge treatments; check the active trials listed on ClinicalTrials.gov. Additionally, while no specific patient organizations are identified, resources like GARD (rarediseases.info.nih.gov) can provide valuable information and support. Participating in a natural history study could also contribute to the understanding of this condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 7 companies have orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.